Catalent today announced that it will present at the upcoming conference, ‘Outsourcing in Clinical Trials 2020 – A Virtual Experience’.

Catalent today welcomed the news by Humanigen, Inc., that it has dosed the first COVID-19 patient in its previously announced Phase 3 study for lenzilumab.

Catalent today announced that two of its experts will present at upcoming virtual industry conferences: CPhI North America Webinar Week; and Clinical Trial Supply 2020 – A Virtual Experience.

Catalent today announced that it has been recognized by the Royal Society for the Prevention of Accidents for its health and safety practices, achieving a silver award for a second consecutive year.

Catalent today announced the appointment of Ricci Whitlow as President, Clinical Supply Services. Ms. Whitlow succeeds Paul Hegwood, who plans to retire in March 2020.

Catalent, a global leader in clinical supply services, today announced the launch of FlexDirect™, a new direct-to-patient service for clinical trials.

Catalent was recently awarded a certificate of recognition from the Tangzhen, China government to acknowledge the company’s successful investment and operations in the region.

Catalent today announced the launch of its new CTSuccess™ clinical trial planning service, designed to support trial sponsors with earlier, more proactive and robust clinical supply chain planning, and reduce the risk of delays and budget overspend common to clinical trials as they progress.

Catalent today announced that Ann McMahon, Program Director, Clinical Supply Services and Drug Product Technologies Integration, will participate in a panel session titled “Cell and Gene Therapy Logistics” at the upcoming Health and Personal Care Logistics Conference (HPCLC) on Oct. 28 – 30, 2019.